Global health officials today announced a pause in the clinical trial of four investigational Ebola drugs in the Democratic Republic of Congo (DRC) outbreak region after an early look at the data found that two of the drugs—Regeneron and mAb 114—stood out as more effective.

In other outbreak developments, the DRC reported 38 more cases since Aug 9, lifting the outbreak total past 2,800 to 2,831.

Promising Regeneron findings triggered pause

(CC BY-ND 2.0), flickr, UNMEER/Martine Perret

Read more at CIDRAP…